Effects of minocycline on regional cerebral blood flow in schizophrenia (2010)
- Authors:
- USP affiliated authors: CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; ZUARDI, ANTONIO WALDO - FMRP ; GUIMARÃES, FRANCISCO SILVEIRA - FMRP
- Unidade: FMRP
- Subjects: ESQUIZOFRENIA; ANTIPSICÓTICOS
- Language: Inglês
- Imprenta:
- Source:
- Título: European Neuropsychopharmacology
- Volume/Número/Paginação/Ano: v. 20, supl. 3, p. S290, res. P.1.e.004, 2010
- Conference titles: Congress of the European College of Neuropsychopharmacology (ECNP)
-
ABNT
MARQUE, C. et al. Effects of minocycline on regional cerebral blood flow in schizophrenia. European Neuropsychopharmacology. Amsterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 26 dez. 2025. , 2010 -
APA
Marque, C., Chaves, C., Wichert-Ana, L., Crippa, J. A. de S., Zuardi, A. W., Baker, G. B., et al. (2010). Effects of minocycline on regional cerebral blood flow in schizophrenia. European Neuropsychopharmacology. Amsterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. -
NLM
Marque C, Chaves C, Wichert-Ana L, Crippa JA de S, Zuardi AW, Baker GB, Guimarães FS, Dursun SM, Hallak JEC. Effects of minocycline on regional cerebral blood flow in schizophrenia. European Neuropsychopharmacology. 2010 ; 20 S290.[citado 2025 dez. 26 ] -
Vancouver
Marque C, Chaves C, Wichert-Ana L, Crippa JA de S, Zuardi AW, Baker GB, Guimarães FS, Dursun SM, Hallak JEC. Effects of minocycline on regional cerebral blood flow in schizophrenia. European Neuropsychopharmacology. 2010 ; 20 S290.[citado 2025 dez. 26 ] - Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial]
- Canabidiol: possíveis aplicacões terapêuticas em psicopatologias
- A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
- Possible therapeutic uses of cannabidiol in anxiety disorders and schizophrenia
- Cannabidiol, a cannabis sativa constituent, as an antipsycholic drug
- Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder
- Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning?
- Cannabidiol: an anxiolytic or an antipsychotic new drug?
- Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizopherenia: an update
- Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
